Rectal Resection with CC DRG Reimbursement Guide

DRG 333 covers rectal resection procedures with a Complication or Comorbidity and reflects higher resource use than uncomplicated resections. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because clinical complexity influences Medicare payment levels.

DRG 333 Overview

DRG 333 covers inpatient stays for patients undergoing rectal resection procedures when a complication or comorbidity is present. This Diagnosis-Related Group groups cases by operative complexity and associated clinical conditions that increase resource use. It matters for Medicare payment because the presence of a Complication or Comorbidity alters relative reimbursement compared with uncomplicated resections. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus affect hospital inpatient payment.

DRG 333 Overview

Perioperative optimization and Enhanced Recovery After Surgery (ERAS) intervention trials: randomized or pragmatic studies testing multimodal perioperative protocols (eg, fluid management, analgesic regimens minimizing opioids, early feeding, bowel prep variations) in adults undergoing elective or urgent rectal resection with documented comorbidities. These trials focus on the immediate perioperative period and include patients with complicated rectal disease (eg, cancer, inflammatory bowel disease) who meet the DRG criteria, aiming to reduce length of stay, surgical complications, and readmission. Results are directly relevant to surgeons, hospital quality teams, and payers because improved protocols can lower resource use, complication-related costs, and variability in reimbursements for this high-cost DRG.
Comparative effectiveness studies of surgical technique and anastomotic management: prospective cohort studies or randomized trials comparing approaches such as low anterior resection with hand-sewn versus stapled anastomosis, sphincter-sparing versus more radical resections, or selective diverting stoma use in patients with CC-level complications. These studies enroll patients with locally advanced disease, prior pelvic surgery, or high-risk features for anastomotic leak to evaluate clinical outcomes (leak rates, reoperation, permanent stoma) and intermediate resource utilization. Findings inform surgeons and payers about which operative choices balance oncologic or functional outcomes against complication-related costs that drive DRG-level payments.
Post-discharge outcomes and cost-effectiveness studies targeting complications and rehabilitation: observational and interventional studies assessing patterns of post-acute care (home health, skilled nursing, outpatient wound/stoma care), rates and drivers of readmission for infection or obstruction, and economic analyses of surveillance pathways in the months after rectal resection with CC. These studies include patients discharged after rectal resection who experienced in-hospital complications and aim to identify predictors of costly readmissions and durable functional outcomes. Results help case managers, discharge planners, and payers optimize post-acute services to reduce avoidable readmissions and overall episode-of-care costs associated with this DRG.

Perioperative optimization and Enhanced Recovery After Surgery (ERAS) intervention trials: randomized or pragmatic studies testing multimodal perioperative protocols (eg, fluid management, analgesic regimens minimizing opioids, early feeding, bowel prep variations) in adults undergoing elective or urgent rectal resection with documented comorbidities. These trials focus on the immediate perioperative period and include patients with complicated rectal disease (eg, cancer, inflammatory bowel disease) who meet the DRG criteria, aiming to reduce length of stay, surgical complications, and readmission. Results are directly relevant to surgeons, hospital quality teams, and payers because improved protocols can lower resource use, complication-related costs, and variability in reimbursements for this high-cost DRG.
Comparative effectiveness studies of surgical technique and anastomotic management: prospective cohort studies or randomized trials comparing approaches such as low anterior resection with hand-sewn versus stapled anastomosis, sphincter-sparing versus more radical resections, or selective diverting stoma use in patients with CC-level complications. These studies enroll patients with locally advanced disease, prior pelvic surgery, or high-risk features for anastomotic leak to evaluate clinical outcomes (leak rates, reoperation, permanent stoma) and intermediate resource utilization. Findings inform surgeons and payers about which operative choices balance oncologic or functional outcomes against complication-related costs that drive DRG-level payments.
Post-discharge outcomes and cost-effectiveness studies targeting complications and rehabilitation: observational and interventional studies assessing patterns of post-acute care (home health, skilled nursing, outpatient wound/stoma care), rates and drivers of readmission for infection or obstruction, and economic analyses of surveillance pathways in the months after rectal resection with CC. These studies include patients discharged after rectal resection who experienced in-hospital complications and aim to identify predictors of costly readmissions and durable functional outcomes. Results help case managers, discharge planners, and payers optimize post-acute services to reduce avoidable readmissions and overall episode-of-care costs associated with this DRG.

OpenPayer

Summary & Overview

Rectal Resection with CC: Inpatient Reimbursement Overview

DRG 333 Overview

OpenPayer

Summary & Overview

Rectal Resection with CC: Inpatient Reimbursement Overview

DRG 333 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes